Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-047441
Filing Date
2024-11-13
Accepted
2024-11-13 08:50:52
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrsn-20240930.htm   iXBRL 10-Q 1425273
2 EX-31.1 exhibit31110-qfy2024q3.htm EX-31.1 11102
3 EX-31.2 exhibit31210-qfy2024q3.htm EX-31.2 11120
4 EX-32.1 exhibit32110-qfy2024q3.htm EX-32.1 5750
  Complete submission text file 0001628280-24-047441.txt   6245002

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrsn-20240930.xsd EX-101.SCH 39875
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrsn-20240930_cal.xml EX-101.CAL 52747
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrsn-20240930_def.xml EX-101.DEF 161121
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrsn-20240930_lab.xml EX-101.LAB 536632
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrsn-20240930_pre.xml EX-101.PRE 385771
80 EXTRACTED XBRL INSTANCE DOCUMENT mrsn-20240930_htm.xml XML 719897
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38129 | Film No.: 241451391
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)